Cambridge Healthtech Institute’s Inaugural

Emerging Oligonucleotide Modalities

Pursuing Circular RNA, tRNA, and Innovative Editing Approaches

March 11-12, 2025

Cambridge Healthtech Institute’s inaugural conference on Emerging Oligonucleotide Modalities shines light on the incredible creativeness of chemists and biologists in designing new targeted therapies. Equipped with innovative engineering tools and delivery mechanisms, scientists are modifying naturally occurring tRNAs, circular RNAs, and non-coding RNAs, and using editing tools to overcome some of the limitations in existing oligo therapies. The talks highlight some of the newer oligo modalities that are showing a lot of promise in terms of improving efficacy, stability, toxicity, and frequency of administration.

Coverage will include, but is not limited to:

Novel oligo modalities and chemistries for improving efficacy and stability
Use of tRNA, circular RNA, and other RNA modalities as targeted therapies
New engineering tools for increasing potency and safety
Exploring RNA editing, gene editing, prime editing, and base editing as therapeutic options
Formulations and vehicles for targeted tissue and cell-type specific delivery
Designing or degrading RNAs to go after ‘undruggable’ targets
Using AI/machine learning for exploring new oligo modalities

The deadline for priority consideration is August 23^rd, 2024.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: